Clearside Biomedical Enters Material Definitive Agreement
Ticker: CLSDQ · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1539029
| Field | Detail |
|---|---|
| Company | Clearside Biomedical, Inc. (CLSDQ) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $32.5 million, $3.0 million, $110.5 million, $106.5 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
TL;DR
Clearside Biomedical just signed a big deal, details TBD.
AI Summary
Clearside Biomedical, Inc. announced on September 4, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but indicates a significant event for the company.
Why It Matters
This filing signals a significant development for Clearside Biomedical, potentially involving a new partnership, acquisition, or licensing deal that could impact its future operations and stock value.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty, making it a medium-risk event until more information is disclosed.
Key Players & Entities
- Clearside Biomedical, Inc. (company) — Registrant
- September 04, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Alpharetta, Georgia (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Clearside Biomedical, Inc.?
The filing states that Clearside Biomedical, Inc. entered into a material definitive agreement on September 4, 2025, but does not provide specific details about the agreement's nature.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 04, 2025.
What is Clearside Biomedical, Inc.'s state of incorporation?
Clearside Biomedical, Inc. is incorporated in Delaware.
Where are Clearside Biomedical, Inc.'s principal executive offices located?
Clearside Biomedical, Inc.'s principal executive offices are located in Alpharetta, Georgia.
What is the SEC file number for Clearside Biomedical, Inc.?
The SEC file number for Clearside Biomedical, Inc. is 001-37783.
Filing Stats: 787 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2025-09-08 07:16:50
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar
- $32.5 million — " Royalties "), and the Seller received $32.5 million. Pursuant to the Pledge Agreement, the
- $3.0 million — ment, the Seller received an additional $3.0 million from the Purchaser, which the Seller th
- $110.5 million — lty Sub to the Purchaser to cease, from $110.5 million to $106.5 million, (ii) specified excep
- $106.5 m — chaser to cease, from $110.5 million to $106.5 million, (ii) specified exceptions to its
Filing Documents
- clsd-20250904.htm (8-K) — 47KB
- 0000950170-25-113362.txt ( ) — 151KB
- clsd-20250904.xsd (EX-101.SCH) — 24KB
- clsd-20250904_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 4, 2025, Clearside Biomedical, Inc. (the " Company ") entered into an Omnibus Amendment Agreement (the " Amendment ") with Clearside Royalty LLC, a wholly owned subsidiary of the Company (the " Seller "), Healthcare Royalty Partners IV, L.P. (the " Purchaser ") and HCR Clearside SPV, LLC (the " Purchaser Agent "). The Amendment, among other things, amends (i) the Purchase and Sale Agreement, dated as of August 8, 2022 (as amended to date, the " Purchase Agreement "), by and among the Seller, the Purchaser and the Purchaser Agent, (ii) the Contribution and Servicing Agreement, dated August 8, 2022 (as amended to date, the " Contribution Agreement "), by and between the Company and Seller and (iii) the Pledge and Security Agreement (as amended to date, the " Pledge Agreement "), dated as of August 8, 2022, by and between the Company and the Purchaser Agent. Pursuant to the Purchase Agreement, in August 2022, the Seller sold to Purchaser certain of its rights to receive royalty and milestone payments payable to Seller under existing license agreements related to XIPERE (triamcinolone acetonide injectable suspension) or the Company's SCS Microinjector technology (collectively, the " Royalties "), and the Seller received $32.5 million. Pursuant to the Pledge Agreement, the Company pledged the capital stock of the Seller to secure the obligations of the Seller under the Purchase Agreement. Purchaser Agent is entitled to foreclose on such capital stock following the occurrence of certain events. Pursuant to the Amendment, the Seller received an additional $3.0 million from the Purchaser, which the Seller then paid to the Company in exchange for the remaining assets related to the Company's SCS Microinjector technology. In addition, in exchange for the additional transferred assets, the Purchaser also agreed to (i) reduce the amount of aggregate Royalties required for the Purchase Agreement to expire,
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 8, 2025 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer